NEKTAR THERAPEUTICS Uncategorized Contracts & Agreements

40 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Letter Agreement dated as of September 6, 2023 by and between Bristol-Myers Squibb and Company and Nektar Therapeutics
NEKTAR THERAPEUTICS
Pharmaceuticals
2023
Co-Development Agreement, dated as of February 1
NEKTAR THERAPEUTICS
Pharmaceuticals
DE
2021
Description of Securities
NEKTAR THERAPEUTICS
Pharmaceuticals
2020
Investor Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics
NEKTAR THERAPEUTICS
Pharmaceuticals
DE
2018
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
DE
2011
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
NY
2011
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
2011
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
DE
2011
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
2011
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
2011
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
2011
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
DE
2011
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
DE
2011
AMENDEDAND RESTATED COMPENSATIONPLAN FOR NON-EMPLOYEE DIRECTORS
NEKTAR THERAPEUTICS
Pharmaceuticals
2009
LICENSEAGREEMENT byand between ASTRAZENECAAB and NEKTARTHERAPEUTICS DATE:September20, 2009
NEKTAR THERAPEUTICS
Pharmaceuticals
NY
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
NY
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
AL
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
DE
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
DE
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
2009
improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug
NEKTAR THERAPEUTICS
Pharmaceuticals
CA
2009
Current assets
NEKTAR THERAPEUTICS
Pharmaceuticals
2008
Current assets
NEKTAR THERAPEUTICS
Pharmaceuticals
2008
NEKTAR THERAPEUTICS
NEKTAR THERAPEUTICS
Pharmaceuticals
2007
EXHIBIT A EMPLOYEE AGREEMENT
NEKTAR THERAPEUTICS
Pharmaceuticals
2007
[Nektar Letterhead]
NEKTAR THERAPEUTICS
Pharmaceuticals
CA
2006
[Nektar Therapeutics Letterhead]
NEKTAR THERAPEUTICS
Pharmaceuticals
CA
2006
NEKTAR THERAPEUTICS
NEKTAR THERAPEUTICS
Pharmaceuticals
DE
2005
THECORPORATEPLAN FOR RETIREMENTSM (PROFITSHARING/401(K) PLAN) A FIDELITYPROTOTYPE PLAN Non-StandardizedAdoption Agreement No. 001 For use With FidelityBasic Plan Document No. 02
NEKTAR THERAPEUTICS
Pharmaceuticals
2004
THE CORPORATEPLAN FOR RETIREMENTSM FIDELITY BASIC PLAN DOCUMENT NO. 02 2003 FMR Corp. All rights reserved.
NEKTAR THERAPEUTICS
Pharmaceuticals
MA
2004
RESALEREGISTRATION RIGHTS AGREEMENT
NEKTAR THERAPEUTICS
Pharmaceuticals
CA
2003
RESALEREGISTRATION RIGHTS AGREEMENT
NEKTAR THERAPEUTICS
Pharmaceuticals
CA
2003
EMPLOYEERELOCATION REPAYMENT AGREEMENT
NEKTAR THERAPEUTICS
Pharmaceuticals
2003
NUMBER
NEKTAR THERAPEUTICS
Pharmaceuticals
2003
CONFIDENTIAL
NEKTAR THERAPEUTICS
Pharmaceuticals
2002